Share Twitter LinkedIn Facebook Email Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm
FDA Approves TEVIMBRA for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma Gastrointestinal 3 Mins Read
Why isn’t CAR-T Therapy Revolutionizing the Fight Against GI Cancers? 17 Trial Insights from ASCO GI 2025 Gastrointestinal 4 Mins Read
Nivolumab + Ipilimumab Shows Improved Outcomes in MSI-H/dMMR mCRC CheckMate-8HW Trial ASCO GI 2 Mins Read